Oral Delivery of Photopolymerizable Nanogels Loaded with Gemcitabine for Pancreatic Cancer Therapy: Formulation Design, and in vitro and in vivo Evaluations

Adi Yugatama,Ya-Lin Huang,Ming-Jen Hsu,Jia-Pei Lin,Fang-Ching Chao,Jenny KW Lam,Chien-Ming Hsieh

DOI: https://doi.org/10.2147/ijn.s443610

IF: 7.033

2024-04-26

International Journal of Nanomedicine

Abstract:Adi Yugatama, 1, 2, &ast Ya-Lin Huang, 1, &ast Ming-Jen Hsu, 3 Jia-Pei Lin, 1 Fang-Ching Chao, 4 Jenny KW Lam, 5 Chien-Ming Hsieh 1, 5, 6 1 School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, 11031, Taiwan; 2 Department of Pharmacy, Sebelas Maret University, Surakarta, 57126, Indonesia; 3 Department of Pharmacology, Taipei Medical University, Taipei, 11031, Taiwan; 4 CNRS UMR 8612, Institut Galien Paris-Saclay, Université Paris-Saclay, Orsay, 91400, France; 5 Department of Pharmaceutics, School of Pharmacy, University College, London, WC1N 1AX, UK; 6 Ph.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei, 11031, Taiwan &astThese authors contributed equally to this work Correspondence: Jenny KW Lam, Department of Pharmaceutics, School of Pharmacy, University College London, 29– 39 Brunswick Square, London, WC1N 1AX, UK, Email Chien-Ming Hsieh, School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, 11031, Taiwan, Email Background: Gemcitabine (GEM) faces challenges of poor oral bioavailability and extensive first-pass metabolism. Currently, only injectable formulations are available for clinical use. Hence, there is an urgent demand for the development of advanced, efficacious, and user-friendly dosage forms to maintain its status as the primary treatment for pancreatic ductal adenocarcinoma (PDAC). Nanogels (NGs) offer a novel oral drug delivery system, ideal for hydrophilic compounds like GEM. This study aims to develop NGs tailored for GEM delivery, with the goal of enhancing cellular uptake and gastrointestinal permeability for improved administration in PDAC patients. Methods: We developed cross-linked NGs via photopolymerization of methacryloyl for drug delivery of GEM. We reveal characterization, cytotoxicity, and cellular uptake studies in Caco-2 and MIA PaCa-2 cells. In addition, studies of in vitro permeability and pharmacokinetics were carried out to evaluate the bioavailability of the drug. Results: Our results show NGs, formed via photopolymerization of methacryloyl, had a spherical shape with a size of 233.91± 7.75 nm. Gemcitabine-loaded NGs (NGs-GEM) with 5% GelMA exhibited efficient drug loading (particle size: 244.07± 19.52 nm). In vitro drug release from NGs-GEM was slower at pH 1.2 than pH 6.8. Cellular uptake studies indicated significantly enhanced uptake in both MIA PaCa-2 and Caco-2 cells. While there was no significant difference in GEM's AUC and Cmax between NGs-GEM and free-GEM groups, NGs-GEM showed markedly lower dFdU content (10.07 hr∙μg/mL) compared to oral free-GEM (19.04 hr∙μg/mL) after oral administration (p< 0.01), highlighting NGs' efficacy in impeding rapid drug metabolism and enhancing retention. Conclusion: In summary, NGs enhance cellular uptake, inhibit rapid metabolic degradation of GEM, and prolong retention after oral administration. These findings suggest NGs-GEM as a promising candidate for clinical use in oral pancreatic cancer therapy. Keywords: oral delivery, nanogel, gemcitabine, pancreatic cancer Pancreatic cancer remains one of the top ten causes of cancer deaths, which is possibly due to its late stage of recognition. In 2020, it was estimated that 495,773 new cases of pancreatic cancer, and the incidence varied by region and population. 1 Gemcitabine (GEM) is a first-line drug for metastatic pancreatic cancer approved by the Food and Drug Administration (FDA). GEM has demonstrated tremendous efficacy along with clinical benefits over 5-fluorouracil for more than 20 years. 2 The drug has demonstrated wide-spectrum application in various solid tumors. Despite exhibiting considerable therapeutic efficacy, GEM is subject to various constraints, such as a relatively brief plasma half-life, as well as limited permeability. 3–5 The brief duration of serum half-life can be ascribed to the swift and extensive process of deamination of GEM by cytidine deaminase (CDA), which is present in several tissues such as blood, liver, and kidneys. 6,7 Cytidine deaminase enzymatically converts GEM into its inactive metabolite, known as 2',2'-difluoro-2'-deoxyuridine (dFdU), which is then eliminated through urinary excretion. Consequently, the administration of GEM necessitates regular dosing intervals in order to sustain a therapeutic concentration of the drug within the systemic circulation. 7 In addition, it is notable that GEM is frequently administered to patients through the intravenous (IV) route, leading to an increased risk of venou -Abstract Truncated-

pharmacology & pharmacy,nanoscience & nanotechnology